Johnson & Johnson has recently spent more than $30 billion on acquisitions, picking up both medtech and pharmaceutical assets along the way. Despite the brisk pace, the healthcare giant’s spending spree may not be over any time soon. CEO Joaquin Duato told investors Tuesday that J&J’s acquisition strategy has not changed, and M&A will remain a key priority. “Our M&A strategy is not going to change. We’ll continue to evaluate opportunities agnostic to the sector and size,” Duato said on an earnings call. “When we think about M&A, we think in decades. We don’t think opportunistically.”
Read the full article: ‘We Think in Decades’: J&J’s $30B Spending Spree May Not Be Over //
Source: https://www.medtechdive.com/news/jnj-earnings-deals-shockwave-abiomed/713292